Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Giles

Showing results (411-420 of 676) with videos related to

Pageof 68
Sort By:
Current Drug Targets|July 23, 2011
Targeting TRAIL towards the clinicDevalingam Mahalingam, Corina N A M Oldenhuis, Eva Szegezdi, et al.
Cancer|April 28, 2004
Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromesQinglong Hu, Amanda L Dey, Ying Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2013
Phase I dose-escalation study of VB-111, an antiangiogenic virotherapy, in patients with advanced solid tumorsAndrew J Brenner, Yael C Cohen, Eyal Breitbart, et al.
Oncotarget|April 1, 2015
Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110α subunit of PI3 kinaseMarco Colamonici, Gavin Blyth, Diana Saleiro, et al.
Optics Express|November 25, 2018
Implementation of plasmonic band structure to understand polariton hybridization within metamaterialsNicholas Sharac, Alexander J Giles, Keith Perkins, et al.
Leukemia Research|July 16, 2003
OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALLBlake Tomkinson, Ray Bendele, Francis J Giles, et al.
Cancer Chemotherapy and Pharmacology|June 5, 2003
Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemiaFrancis J Giles, Gary Guangping Shi, Jorge E Cortes, et al.
Blood|December 12, 2001
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blastsE H Estey, P F Thall, J E Cortes, et al.
Leukemia & Lymphoma|February 1, 1996
Technetium-99m sestamibi scanning in multiple myeloma stem cell transplantationR M Look, S W Lim, A D Waxman, et al.
Cancer|March 7, 2006
Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemiaMaher Albitar, Steven J Potts, Francis J Giles, et al.
Pageof 68

Showing results (411-420 of 676) with videos related to

Sort By:
Pageof 68
Current Drug Targets|July 23, 2011
Targeting TRAIL towards the clinicDevalingam Mahalingam, Corina N A M Oldenhuis, Eva Szegezdi, et al.
Cancer|April 28, 2004
Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromesQinglong Hu, Amanda L Dey, Ying Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2013
Phase I dose-escalation study of VB-111, an antiangiogenic virotherapy, in patients with advanced solid tumorsAndrew J Brenner, Yael C Cohen, Eyal Breitbart, et al.
Oncotarget|April 1, 2015
Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110α subunit of PI3 kinaseMarco Colamonici, Gavin Blyth, Diana Saleiro, et al.
Optics Express|November 25, 2018
Implementation of plasmonic band structure to understand polariton hybridization within metamaterialsNicholas Sharac, Alexander J Giles, Keith Perkins, et al.
Leukemia Research|July 16, 2003
OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALLBlake Tomkinson, Ray Bendele, Francis J Giles, et al.
Cancer Chemotherapy and Pharmacology|June 5, 2003
Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemiaFrancis J Giles, Gary Guangping Shi, Jorge E Cortes, et al.
Blood|December 12, 2001
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blastsE H Estey, P F Thall, J E Cortes, et al.
Leukemia & Lymphoma|February 1, 1996
Technetium-99m sestamibi scanning in multiple myeloma stem cell transplantationR M Look, S W Lim, A D Waxman, et al.
Cancer|March 7, 2006
Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemiaMaher Albitar, Steven J Potts, Francis J Giles, et al.
Pageof 68